Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Apoptosis: A Review of Programmed Cell Death

Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853 · see citing works

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works

The molecular machinery of regulated cell death

Tang, D., Kang, R., Berghe, T. V., Vandenabeele, P., & Kroemer, G. (2019) · Cell Research · doi:10.1038/s41422-019-0164-5 · Cited by 2,595 · see citing works

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111 · see citing works

Death and anti-death: tumour resistance to apoptosis

Igney, F. H., & Krammer, P. H. (2002) · Nature reviews. Cancer · doi:10.1038/nrc776 · Cited by 2,073 · see citing works

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,901 · see citing works

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825 · see citing works

Structural basis of PROTAC cooperative recognition for selective protein degradation

Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242 · see citing works

Programmed Anuclear Cell Death Delimits Platelet Life Span

Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · see citing works

Targeted protein degradation: expanding the toolbox

Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960 · see citing works

Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics

Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 919 · see citing works

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903 · see citing works

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852 · see citing works

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688 · see citing works

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase

Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517 · see citing works

Bcl-2 family proteins are essential for platelet survival

Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427 · see citing works

Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities

Galdeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Molle, I. V., Birced, I., Hewitt, S. H., Dias, D. M. G., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 424 · see citing works

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383 · see citing works

Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7

Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336 · see citing works

Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action

Riching, K. M., Mahan, S. D., Corona, C. R., McDougall, M. G., Vasta, J. D., Robers, M. B., Urh, M., & Daniels, D. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00692 · Cited by 307 · see citing works

Development of dual and selective degraders of cyclin-dependent kinases 4 and 6

Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272 · see citing works

Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity

Wu, H., Yang, K., Zhang, Z., Leisten, E. D., Li, Z., Xie, H., Liu, J., Smith, K. A., Novakova, Z., Barinka, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00516 · Cited by 180 · see citing works

Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis

Herrant, M., Jacquel, A., Marchetti, S., Belhacène, N., Colosetti, P., Luciano, F., & Auberger, P. (2004) · Oncogene · doi:10.1038/sj.onc.1208069 · Cited by 179 · see citing works

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00928-9 · Cited by 139 · see citing works

BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells

Alford, S. E., Kothari, A., Loeff, F. C., Eichhorn, J. M., Sakurikar, N., Goselink, H. M., Saylors, R. L., Jedema, I., Falkenburg, J. H. F., & Chambers, T. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1849 · Cited by 124 · see citing works

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

Zhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112186 · Cited by 123 · see citing works

BCL-XL overexpression promotes tumor progression-associated properties

Trisciuoglio, D., Tupone, M. G., Desideri, M., Martile, M. D., Gabellini, C., Buglioni, S., Pallocca, M., Alessandrini, G., D’Aguanno, S., & Bufalo, D. D. (2017) · Cell Death and Disease · doi:10.1038/s41419-017-0055-y · Cited by 113 · see citing works

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

Patterson, C. M., Balachander, S. B., Grant, I., Pop-Damkov, P., Kelly, B. D., McCoull, W., Parker, J. S., Giannis, M. P., Hill, K. J., Gibbons, F. D., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01631-8 · Cited by 97 · see citing works

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X _L

Zhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications · doi:10.1039/c9cc07217a · Cited by 86 · see citing works

Racemic and Asymmetric Diels−Alder Reactions of 1-(2-Oxazolidinon-3-yl)-3-siloxy-1,3-butadienes

Janey, J. M., Iwama, T., Kozmin, S. A., & Rawal, V. H. (2000) · The Journal of Organic Chemistry · doi:10.1021/jo005619y · Cited by 82 · see citing works

Development of CDK2 and CDK5 Dual Degrader TMX‐2172

Teng, M., Jiang, J., He, Z., Kwiatkowski, N. P., Donovan, K. A., Mills, C. E., Victor, C., Hatcher, J. M., Fischer, E. S., Sorger, P. K., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004087 · Cited by 82 · see citing works

Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1

Murray, J. B., Davidson, J. E. P., Chen, I., Davis, B. J., Dokurno, P., Graham, C. J., Harris, R., Jordan, A. M., Matassova, N., Pedder, C., et al. (2019) · ACS Omega · doi:10.1021/acsomega.9b00611 · Cited by 76 · see citing works

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines

Zhang, X., He, Y., Zhang, P., Budamagunta, V., Lv, D., Thummuri, D., Yang, Y., Pei, J., Yuan, Y., Zhou, D., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112397 · Cited by 71 · see citing works

PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors

Zhang, P., Zhang, X., Liu, X., Khan, S. U., Zhou, D., & Zheng, G. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00017 · Cited by 27 · see citing works

The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy

Vogler, M., Braun, Y., Smith, V. M., Westhoff, M., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 448 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · see citing works

Proximity-Based Modalities for Biology and Medicine

Liu, X., & Ciulli, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00395 · Cited by 204 · see citing works

COVID-19 and cellular senescence

Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153 · see citing works

Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy

Han, X., & Sun, Y. (2022) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2022.101062 · Cited by 89 · see citing works

Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x L Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches

Negi, A., & Voisin‐Chiret, A. S. (2022) · ChemBioChem · doi:10.1002/cbic.202100689 · Cited by 68 · see citing works

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective

Han, X., Wei, W., & Sun, Y. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0010 · Cited by 69 · see citing works

The rise of degrader drugs

Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 63 · see citing works

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 66 · see citing works

Novel approaches to targeted protein degradation technologies in drug discovery

Xue, Y., Bolinger, A. A., & Zhou, J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2187777 · Cited by 59 · see citing works

HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation

Xiao, Y.-F., Hale, S., Awasthee, N., Meng, C.-C., Zhang, X., Liu, Y., Ding, H., Huo, Z.-G., Lv, D., Zhang, W.-Z., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.07.010 · Cited by 47 · see citing works

Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma

Rishfi, M., Krols, S., Martens, F., Bekaert, S.-L., Sanders, E., Eggermont, A., Vloed, F. D., Goulding, J. R., Risseeuw, M., Molenaar, J. J., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115033 · Cited by 45 · see citing works

Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders

Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 41 · see citing works

In Silico Computational Studies of Bioactive Secondary Metabolites from Wedelia trilobata against Anti-Apoptotic B-Cell Lymphoma-2 (Bcl-2) Protein Associated with Cancer Cell Survival and Resistance

Gowtham, H. G., Ahmed, F., Anandan, S., Shivakumara, C. S., Bilagi, A., Pradeep, S., Shivamallu, C., Shati, A. A., Alfaifi, M. Y., Elbehairi, S. E. I., et al. (2023) · Molecules · doi:10.3390/molecules28041588 · Cited by 39 · see citing works

Proline Analogues in Drug Design: Current Trends and Future Prospects

Kubyshkin, V., & Mykhailiuk, P. K. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01987 · Cited by 37 · see citing works

Small-Molecule PROTACs for Cancer Immunotherapy

Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 29 · see citing works

Comprehensive Insights Into Sulfanilamido‐Based Medicinal Design and Research

Wang, Y., Wang, J., Mou, L., Zhang, H. Y., Chen, G., & Zhou, C. (2025) · Medicinal Research Reviews · doi:10.1002/med.22115 · Cited by 25 · see citing works

Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer

Wang, X., Wang, S., Mu, H.-X., Xu, K.-Y., Wang, X., Shi, J.-T., Cui, Q.-H., Zhang, L., & Chen, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114821 · Cited by 24 · see citing works

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

Wang, C., Zhang, Y., Zhang, T., Shi, L., Geng, Z., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2076675 · Cited by 21 · see citing works

Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

Pal, P., Zhang, P., Poddar, S. K., & Zheng, G. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2116311 · Cited by 18 · see citing works

Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies

López, J., Llop‐Hernández, À., Verdura, S., Serrano‐Hervás, E., Martinez‐Balibrea, E., Bosch‐Barrera, J., Teixidor, E., López‐Bonet, E., Martı́n-Castillo, B., Josep Sardanyés, A., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02379-y · Cited by 18 · see citing works

Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment

Huang, L. H., Shao, J., Lai, W., Gu, H., Yang, J., Shi, S., Wufoyrwoth, S., Song, Z., Zou, Y., Xu, Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116159 · Cited by 16 · see citing works

Targeted degradation of specific TEAD paralogs by small molecule degraders

Chen, H., Gridnev, A., Schlamowitz, N. S., Hu, W., Dey, K., Zheng, G., & Misra, J. R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37829 · Cited by 14 · see citing works

MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53

Chang, M., Gao, F., Chen, J., Gnawali, G. R., & Wang, W. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0022 · Cited by 14 · see citing works

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology

Zhao, X., Chen, Y., Su, H., & Zhang, L. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230004 · Cited by 14 · see citing works

B‐cell lymphoma‐2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy

Gong, Q., Wang, H., Zhou, M., Zhou, L., Wang, R., & Li, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21999 · Cited by 13 · see citing works

Thalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN

Wang, J., Heinz, M., Han, K., Shah, V. J., Hasselbeck, S., Schwalm, M. P., Rathore, R., Hummer, G., Zhou, J., Đikić, I., et al. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.101960 · Cited by 13 · see citing works

PROTAC as a novel anti-cancer strategy by targeting aging-related signaling

Peng, Y., Liu, D., Huang, D., Inuzuka, H., & Liu, J. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.004 · Cited by 10 · see citing works

mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation

Xue, X., Zhang, C., Li, X., Wang, J., Zhang, H., Feng, Y., Xu, N., Li, H., Tan, C., Jiang, Y., et al. (2024) · MedComm · doi:10.1002/mco2.478 · Cited by 9 · see citing works

Design, Synthesis, and Evaluation of BCL‐2 Targeting PROTACs

Bricelj, A., Ng, Y. L. D., Gobec, M., Kuchta, R. D., Hu, W., Javornik, Š., Rožič, M., Gütschow, M., Zheng, G., Krönke, J., et al. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202400430 · Cited by 10 · see citing works

Application of proteolysis targeting chimeric (PROTAC) technology in protein regulation and drug development

He, Y., Liao, T., Wang, X., Xiao, Q. H., Wang, H., He, R. R., Zhao, C., Tian, X., Gao, Q., & Hao, L. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108846 · Cited by 8 · see citing works

Discovery of XZ338, a highly potent BCL-XL degrader

Zhang, X., Thummuri, D., Hu, W., Liu, X., Zhang, P., Zhou, S., Zhou, D., & Zheng, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117624 · Cited by 7 · see citing works

Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader

Zhang, P., Thummuri, D., Hu, W., Khan, S. U., He, Y., Zhang, X., Pal, P., Lv, D., Zhou, D., & Zheng, G. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00119f · Cited by 7 · see citing works

Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies

Wu, Y., Zhang, J., Zhu, X., & Zhang, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215808 · Cited by 8 · see citing works

Discovery of Dual BCL-xL/BCL-w Degraders by Exploiting the Bis(sulfonyl)benzene Ring of ABT-263 as a Linkage Vector

Poddar, S. K., Yang, Y., Pal, P., Jin, Z., Pei, J., Xiao, Y., Hu, W., Zhang, P., Adekunbi, P., Thummuri, D., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01834 · Cited by 4 · see citing works

Mitochondrial priming in therapy-induced senescence: implications for CAR-T/NK immunosenolytic therapy

Menéndez, J. A., Lupu, R., Martı́n-Castillo, B., Josep Sardanyés, A., Alarcón, T., Verdura, S., & Cuyàs, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1695244 · Cited by 5 · see citing works

Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway

Xu, Y., Lei, Z., Zhu, J., & Wan, L. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.07.045 · Cited by 4 · see citing works

Computational Modeling of PROTAC Ternary Complexes and Linker Design

Miller, S. A., Andrianov, G. V., Mischley, V., Wharton, K. A., Chen, J. J., & Karanicolas, J. (2022) · doi:10.1002/9783527836208.ch5 · Cited by 4 · see citing works

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Minimizes Ex Vivo Reservoirs from Patients

Chang, L.-C., Yin, M. T., Laird, G. M., Ritter, K. D., Shah, J., & Debnath, A. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062772 · Cited by 3 · see citing works

The BCL-2 Family Proteins: Insights Into Their Mechanism of Action and Therapeutic Potential

van Delft, M. F., & Dewson, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00141-3 · Cited by 3 · see citing works

Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery

Yang, J., Zhang, Y., Zhang, M., Xing, D., & Wang, C. (2025) · Materials Today Advances · doi:10.1016/j.mtadv.2025.100644 · Cited by 3 · see citing works

Unveiling BCL-xL-specific PROTAC efficiency and dissociation pathways using native mass spectrometry

Gadallah, M. I., Nonhof, K. L., Nayak, D., Zhang, P., Dioli, O. E., Zheng, G., Olsen, S. K., Zhou, D., & Brodbelt, J. S. (2026) · Chemical Science · doi:10.1039/d5sc07400b · Cited by 2 · see citing works

Disrupting the MC1R/α‐MSH‐pCREB‐MITF Axis: Rhein‐based PROTAC D16 as a Potent Melanogenesis Inhibitor

Xu, M., Zhang, Z., Zhang, P., He, X., Zeng, H., Chen, M., Wang, Y., Xia, Y., Lu, W., Huang, S., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501651 · Cited by 2 · see citing works

Kill Two Birds with One Stone: An Efficient and Potent AR CBS-Targeted Degrader Reverses Breast Cancer Resistance via Concurrent AR Degradation and ERα Transcriptional Suppression

Wu, Y., Xie, B., Liang, J., Wei, D., Wang, Y., Yin, Y., Deng, X., Wang, C., Ni, J., Yang, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01926 · Cited by 1 · see citing works

Dual-targeting Bcl-2-mediated apoptosis and synergistic pathways: Combinatorial strategies to overcome therapeutic resistance in cancer

Cheng, J., Wang, H., Zhang, Y., & Liu, G. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117802 · Cited by 1 · see citing works

Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death

Abdelsalam, M. A. M., Halilovic, M., Ashry, R., Nassar, H., Erdmann, F., Schmidt, M., Krämer, O. H., & Sippl, W. (2026) · Pharmaceuticals · doi:10.3390/ph19050756 · Cited by 1 · see citing works

Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma

Ho, M. P., Skouradaki, E., Baritaki, S., Otumo, E., & Bonavida, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189395 · Cited by 1 · see citing works

Discovery of Novel VEGFR-2-PROTAC Degraders Based on the Localization of Lysine Residues via Recruiting VHL for the Treatment of Gastric CancerPreprint

Wang, X. R., Wang, S., Mu, H.-X., Xu, K., Wang, X. T., Shi, J. T., Cui, Q.-H., Zhang, L. W., & Chen, S. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4163279 · Cited by 1 · see citing works

Ginsenosides as Promising Therapeutic Agents for Glioma: Mechanisms of Action and Future Perspectives

Moftakhar, A., Najafi, S., Khoshnam, S. E., & Farzaneh, M. (2024) · Current Chemical Biology · doi:10.2174/0122127968305352240929154003

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Eliminates Ex Vivo ReservoirsPreprint

Chang, L.-C., Yin, M. T., Laird, G. M., Ritter, K. D., Shah, J., & Debnath, A. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.16.618723

Synthesis and Biological Characterization of Dual-Specific Proteolysis Target Chimeras (Protacs) for the Kinases Flt3-Itd and Mapk14 with Antileukemic ActivityPreprint

Abdelsalam, M. A. M., Halilovic, M., Ashry, R., Nassar, H., Schmidt, M., Krämer, O. H., & Sippl, W. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5336245

PROTACS- targeted protein degradation as a path to precision cancer therapeutics

Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001

Discovery of potent indole-2-one-based BRD4 PROTACs for the treatment of acute myeloid leukemia

Wang, Z., Wang, Y., Ge, F., Zhang, J., Xiang, R., & Chen, S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109337

Recent advance in the targeted protein degradation technology for overcoming acute leukemia

Jin, X., Shi, Z., Liang, Z., Chen, J., Wang, C., Lou, Y., Cao, X., Zhu, L., Zhao, Y., Zhao, C., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100331

Targeting BCL ‐ xL in Myeloid Malignancies: From Inhibitors to PROTAC

Cilloni, D., Ferrando, A., & Frassoni, F. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71036

From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL‐2/BCL‐XL Inhibition

Mohiuddin, M. (2026) · Health Science Reports · doi:10.1002/hsr2.72506

BindingDB Entry 50018785: Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer.

BindingDB (2024) · UC San Diego · doi:10.7270/q2tm7gcn

BindingDB Entry 50021852: Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.

BindingDB (2025) · UC San Diego · doi:10.7270/q2v129hx

BindingDB Entry 50022871: Proline Analogues in Drug Design: Current Trends and Future Prospects.

BindingDB (2026) · UC San Diego · doi:10.7270/q2v129nq

BindingDB Entry 50021132: Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.

BindingDB (2025) · UC San Diego · doi:10.7270/q21g0rv2

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

Zhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112186 · Cited by 123 · see citing works

Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL

Nayak, D., Lv, D., Yuan, Y., Zhang, P., Hu, W., Nayak, A., Ruben, E. A., Lv, Z., Sung, P., Hromas, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46922-4 · Cited by 55 · see citing works

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X _L

Zhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications · doi:10.1039/c9cc07217a · Cited by 86 · see citing works

Structural Insights into PROTAC-Mediated Degradation of Bcl-xL

Chung, C., Dai, H., Fernández, E., Tinworth, C. P., Churcher, I., Cryan, J., Denyer, J. C., Harling, J. D., Konopacka, A., Queisser, M. A., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00266 · Cited by 86 · see citing works

Discovery of Dual BCL-xL/BCL-w Degraders by Exploiting the Bis(sulfonyl)benzene Ring of ABT-263 as a Linkage Vector

Poddar, S. K., Yang, Y., Pal, P., Jin, Z., Pei, J., Xiao, Y., Hu, W., Zhang, P., Adekunbi, P., Thummuri, D., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01834 · Cited by 4 · see citing works